Menu
Recruiting NCT07325942

Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure

No phase Interventional Chronic Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: low-volume high intensity interval training, High volume high intensity interval training, Standard medical treatment.
Who it may be relevant to
Registry conditions: Chronic Heart Failure. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients

Interventions

  • Other low-volume high intensity interval training
    Low-volume HIIT (LV-HIIT) is a particularly time-efficient subtype of interval training, which has gained increasing attention in recent years. As per the previous definition, these brief training protocols typically involve≤10 min of intense exercise within a session lasting≤30 min including warm-up, recovery phases between intervals, and cool-down
  • Other High volume high intensity interval training
    long (2-4 min) bouts of high (not maximum) intensity exercise interspersed with recovery periods which have wide varieties in the protocols according to the intensity, duration, and number of intervals performed
  • Drug Standard medical treatment
    standard medical treatment for chronic heart failure as per international guidlines

Primary outcome measures

  • 6 minute walk test [Time frame: at enrolment and at the end of treatment at 8 weeks]
  • 2D Echocardiographic parameters [Time frame: at enrollment and at the end of treatment at 8 weeks]
Secondary outcome measures (1)
  • Minnesota living with heart failure questionnaire (MLHFQ) [Time frame: at enrollment and at the end of treatment at 8 weeks]

Eligibility criteria

Inclusion criteria

  • Chronic stable heart failure patient with reduced ejection fraction (EF <40)
  • Age Above 18 years old
  • Both males and females
  • The ability to provide informed consent

Exclusion criteria

  • Based on the Scientific Statement from the American Heart Association: contraindications for exercise Testing and Training. (Fletcher et al., 2013)
  • Acute myocardial infarction (MI), within 2 days
  • Ongoing unstable angina
  • Uncontrolled cardiac tachy or brady arrhythmia with hemodynamic compromise
  • Active endocarditis
  • Symptomatic severe aortic stenosis
  • Decompensated heart failure
  • Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis
  • Acute myocarditis or pericarditis
  • Acute aortic dissection
  • Physical disability that precludes safe and adequate testing or training
  • Known obstructive left main coronary artery stenosis
  • Hypertrophic obstructive cardiomyopathy with severe resting gradient
  • Recent stroke or transient ischemic attack
  • Mental impairment with limited ability to cooperate
  • Resting hypertension with systolic or diastolic blood pressures >200/110 mmHg
  • Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism
  • Acute decompensated heart failure NYHA class IV

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Cairo University — Cairo

Identifiers

NCT: NCT07325942 · P.T.REC/012/005825

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗